Abstract
Event trials using statin therapy have shown a beneficial effect on rates of cardiovascular events. The three statins that have been used in long-term trials have shown generally similar effects on rates of myocardial infarction, stroke, revascularizations, and mortality. Safety data appear to be comparable for lovastatin, pravastatin, and simvastatin. Long-term trials of other statins are in progress or pending. The question of how much low-density lipoprotein cholesterol should be lowered may be answered by studies currently in progress.
MeSH terms
-
Coronary Disease / mortality
-
Coronary Disease / prevention & control*
-
Dose-Response Relationship, Drug
-
Drug Administration Schedule
-
Female
-
Follow-Up Studies
-
Humans
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
-
Hyperlipidemias / diagnosis
-
Hyperlipidemias / drug therapy*
-
Hyperlipidemias / mortality
-
Male
-
Primary Prevention / methods
-
Randomized Controlled Trials as Topic
-
Risk Assessment
-
Severity of Illness Index
-
Survival Analysis
-
Treatment Outcome
Substances
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors